SCHEMBL17667384

SCHEMBL17667384

COC(=O)C[C@H](C)[C@H](N)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.44
SLC1A1 P43005 2/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
TSHR P16473 4/20 0.37
HSD17B10 Q99714 1/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
BHMT Q93088 1/20 0.33
KCNA5 P22460 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
LAP3 P28838 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571632 1.00 SLC7A5 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2TSHR
SCHEMBL2031755 1.00 SLC7A5 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2TSHR
SCHEMBL1927791 0.82 SLC7A5 (0.43) SLC7A5SLC1A1SLC1A3SLC1A2TSHR
SCHEMBL29205847 0.80 TSHR (0.42) SLC7A5SLC1A1TSHRHSD17B10MGAM
SCHEMBL5077875 0.79 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL5081302 0.79 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL23277581 0.79 SLC7A5 (0.40) SLC7A5SLC1A1SLC1A3SLC1A2MMP1
SCHEMBL4706239 0.79 CYP2D6 (0.41) SLC7A5SLC1A1SLC1A3SLC1A2GAA
SCHEMBL333966 0.79 CYP2D6 (0.41) SLC7A5SLC1A1SLC1A3SLC1A2GAA
SCHEMBL27419703 0.79 CYP2D6 (0.41) SLC7A5SLC1A1SLC1A3SLC1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3006449-B1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE ALPHA-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[C,E]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID HAMARI CHEMICALS LTD (JP) 2018-01-31 EP disclosed
US-9695112-B2 Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid HAMARI CHEMICALS, LTD. (JP) 2017-07-04 US disclosed
US-9695112-B2 Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid HAMARI CHEMICALS, LTD. (JP) 2017-07-04 US disclosed
US-9695112-B2 Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid HAMARI CHEMICALS, LTD. (JP) 2017-07-04 US disclosed
US-20160102045-A1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID HAMARI CHEMICALS, LTD. (JP) 2016-04-14 US disclosed
US-20160102045-A1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID HAMARI CHEMICALS, LTD. (JP) 2016-04-14 US disclosed
US-20160102045-A1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID HAMARI CHEMICALS, LTD. (JP) 2016-04-14 US disclosed
EP-3006449-A1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE -AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID Hamari Chemicals, Ltd. (JP) 2016-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102045-A1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID AADAT, ALDH7A1, BCAT1 SLC7A5 31/4885SLC1A1 111/4885SLC1A3 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.